文献速递MDS 与骨髓增殖性肿瘤

造血干祖细胞来源的基因表达评分可预测骨髓纤维化生存

A stem and progenitor cell-derived gene expression signature is prognostic for survival in myelofibrosis.
PubMed 文献 · Blood · 2026-01-01

本研究对358例骨髓纤维化患者血液进行bulk RNA-seq,结合单细胞RNA-seq数据开发预后模型,并在两个独立队列(170例和100例)中用NanoString验证。识别出24基因加权表达评分MPN24,高评分者5年OS显著更差(25.5% vs 86.9%,HR=9.81,P=4.0e-11;23.5% vs 75.9%,HR=6.40,P=1.8e-7),且在多变量分析中独立于DIPSS、DIPSS plus、MIPSS70和MIPSS70 plus v2.0等现有模型,并可改善中危患者的风险分层。

要点

  • MPN24高评分与骨髓纤维化患者更差的5年OS显著相关。
  • MPN24独立于DIPSS、DIPSS plus、MIPSS70及MIPSS70 plus v2.0等现有模型。
  • MPN24尤其改善DIPSS中危和MIPSS70中危/高危患者的风险分层。

核心结论

  • MPN24是源自造血干祖细胞的基因表达评分,与骨髓纤维化患者OS独立相关,并改善现有风险分层模型。

研究设计与样本

  • 对358例骨髓纤维化患者血液进行bulk RNA-seq,分为训练和测试队列,并利用Lin-CD34+ MF HSPC的单细胞RNA-seq数据指导模型开发。
  • 使用NanoString检测在两个独立骨髓纤维化患者队列(170例和100例)中验证最终模型。

主要发现

  • 识别出24基因加权求和表达评分MPN24,可预测总生存期。
  • 在170例患者队列中,MPN24高评分者5年OS为25.5%,低评分者为86.9%(HR=9.81,P=4.0e-11)。
  • 在100例患者队列中,MPN24高评分者5年OS为23.5%,低评分者为75.9%(HR=6.40,P=1.8e-7)。
  • MPN24高评分与已知 confer 不良风险的临床、突变和核型特征相关。
  • 多变量分析中,MPN24在纳入DIPSS、DIPSS plus、MIPSS70和MIPSS70 plus v2.0等协变量后仍保持独立预后意义,并分别为这些模型增加显著预后价值(P=1.6e-5、4.0e-6、1.5e-6和5.4e-4)。

关键数值与推荐

  • MPN24高评分 vs 低评分:5年OS 25.5% vs 86.9%(HR=9.81,P=4.0e-11,n=170)。
  • MPN24高评分 vs 低评分:5年OS 23.5% vs 75.9%(HR=6.40,P=1.8e-7,n=100)。
  • MPN24对DIPSS、DIPSS plus、MIPSS70和MIPSS70 plus v2.0的增量预后价值P值分别为1.6e-5、4.0e-6、1.5e-6和5.4e-4。

临床怎么用

  • MPN24评分可用于骨髓纤维化患者风险分层,尤其有助于细化DIPSS中危和MIPSS70中危/高危患者的预后评估。
  • MPN24独立于现有临床和基因组预后变量,可与现有风险模型联合使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this study, we hypothesized that transcriptomic features among disease-driving hematopoietic stem and progenitor cells (HSPC) could improve current paradigms for risk stratification in myelofibrosis (MF). Therefore, we performed bulk RNA sequencing (RNA-seq) of blood from 358 patients with MF, split into training and test cohorts. Single-cell RNA-seq data from Lin-CD34+ MF HSPCs were used to guide the development of a prognostic model trained on the bulk RNA-seq data. A NanoString assay was used to validate our final model in 2 independent cohorts of patients with MF. We identified a 24-gene weighted-sum expression score (MPN24) that was prognostic of overall survival (OS). In 2 independent cohorts of 170 and 100 patients with MF, MPN24-high scoring patients had worse 5-year OS compared with MPN24-low scoring patients (25.5% vs 86.9%, hazard ratio [HR] = 9.81, P = 4.0e-11 and 23.5% vs 75.9%, HR, 6.40, P = 1.8e-7, respectively). MPN24-high was also associated with clinical, mutation and karyotypic features known to confer adverse risk in MF. The MPN24 score retained independent prognostic significance in multivariable analysis incorporating these covariates and existing risk stratification models including Dynamic International Prognostic Scoring System (DIPSS), DIPSS plus, Mutation-Enhanced International Prognostic Score System (MIPSS70), and MIPSS70 plus version 2.0, adding significant prognostic value to these risk stratification models (P = 1.6e-5, 4.0e-6, 1.5e-6, and 5.4e-4, respectively). The MPN24 score was particularly useful in improving risk-stratification of DIPSS-intermediate, and MIPSS70-intermediate and high-risk patients. MPN24 is an HSPC-derived gene expression score that is associated with OS independent of clinical and genomic prognostic variables and improves risk stratification in MF.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Medeiros JJF, Zeng AGX, Bansal S, et al. A stem and progenitor cell-derived gene expression signature is prognostic for survival in myelofibrosis. Blood. 2026. PMID: 41481381. doi:10.1182/blood.2025030094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。